LifeSci Capital Initiates a Buy Rating on Zymeworks (ZYME)
LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...
Lifesci Capital Has Pessimistic View of ATXS FY2025 Earnings
Stock analysts at Lifesci Capital cut their FY2025 earnings per share estimates for Astria Therapeutics in a research report ...
What is Lifesci Capital’s Forecast for CRBP Q1 Earnings?
Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus ...
Molecular Partners (MOLN) Initiated with a Buy at LifeSci Capital
In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Molecular Partners (MOLN – Research ...
Fintel on MSN4 天
LifeSci Capital Initiates Coverage of Molecular Partners AG - Depositary Receipt () (MOLN ...
Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Molecular Partners AG - Depositary Receipt () ...
Fintel on MSN3 天
LifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform ...
Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a ...
Nasdaq12 天
LifeSci Capital Initiates Coverage of Protara Therapeutics (TARA) with Outperform ...
Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a Outperform recommendation. As of March 4, 2025, the average one-year price ...
Nasdaq12 天
LifeSci Capital Initiates Coverage of Zymeworks (ZYME) with Outperform Recommendation
The projected annual non-GAAP EPS is -1.45. EcoR1 Capital holds 15,028K shares representing 21.60% ownership of the company. In its prior filing, the firm reported owning 13,437K shares ...